IMMUNIZATION METHODS

By L. NAIRM

CONTENTS PART I IN SILICO METHODS 1 USE OF IMGT® DATABASES AND TOOLS FOR ANTIBODY ENGINEERING AND HUMANIZATION 2 COMPUTER-ASSISTED MODELING OF ANTIBODY VARIABLE DOMAINS PART II GENERATION OF DIVERSITY 3 CLONING SINGLE-CHAIN ANTIBODY FRAGMENTS (SCFV) FROM HYRBIDOMA CELLS 4 HUMAN IN-CELL SCFV LIBRARY FROM IN?LTRATING B CELL 5 CONSTRUCTION OF HUMAN NAIVE ANTIBODY GENE LIBRARIES 6 SYNTHETIC CUSTOMIZED SCFV LIBRARIES 7 SELECTION OF STABLE SCFV ANTIBODIES BY PHAGE DISPLAY 8 GENERATION OF SINGLE DOMAIN ANTIBODY FRAGMENTS DERIVED FROM CAMELIDS AND GENERATION OF MANIFOLD CONSTRUCTS 9 GENERATION AND ISOLATION OF TARGET-SPECI?C SINGLE-DOMAIN ANTIBODIES FROM SHARK IMMUNE REPERTOIRES 10 GENERATION OF HUMAN SINGLE DOMAIN ANTIBODY REPERTOIRES BY KUNKEL MUTAGENESIS PART III SELECTIONS OF LEAD CANDIDATE 11 PHAGE DISPLAY AND SELECTIONS ON PURI?ED ANTIGENS 12 PHAGE DISPLAY AND SELECTIONS ON CELLS 13 HUMANIZATION BY CDR GRAFTING AND SPECI?CITY-DETERMINING RESIDUE GRAFTING 14 HUMANIZATION BY GUIDED SELECTIONS 15 SELECTION OF ANTIBODY FRAGMENTS BY YEAST DISPLAY 16 EVOLUTION OF ANTIBODIES IN VITRO BY RIBOSOME DISPLAY 17 MAMMALIAN CELL SURFACE DISPLAY OF FULL LENGTH IGG PART IV PRODUCTION OF RECOMBINANT ANTIBODIES 18 PRODUCTION OF ANTIBODY FRAGMENTS IN ESCHERICHIA COLI 19 PRODUCTION OF ANTIBODY DERIVATIVES IN THE METHYLOTROPHIC YEAST PICHIA PASTORIS 20 MONOCLONAL ANTIBODY EXPRESSION IN MAMMALIAN CELLS 21 PRODUCTION OF RECOMBINANT ANTIBODIES IN DROSOPHILA MELANOGASTER S2 CELLS 22 PRODUCTION OF ANTIBODY FRAGMENTS USING THE BACULOVIRUS–INSECT CELL SYSTEM 23 TRANSIENT AND STABLE EXPRESSION OF ANTIBODIES IN NICOTIANA SPECIES PART V VARIABLE DOMAIN OPTIMIZATION 24 MEASURING ANTIBODY–ANTIGEN BINDING KINETICS USING SURFACE PLASMON RESONANCE 25 AF?NITY DETERMINATION OF BIOTINYLATED ANTIBODIES BY FLOW CYTOMETRY 26 AF?NITY MATURATION OF ANTIBODIES: OPTIMIZED METHODS TO GENERATE HIGH-QUALITY SCFV LIBRARIES AND ISOLATE IGG CANDIDATES BY HIGH-THROUGHPUT SCREENING 27 AF?NITY MATURATION BY SEMI-RATIONAL APPROACHES 28 MOLECULAR SCANNING: COMBINING RANDOM MUTAGENESIS, RIBOSOME DISPLAY, AND BIOINFORMATIC ANALYSIS FOR PROTEIN ENGINEERING PART VI FC ENGINEERING 29 FUCOSE-TARGETED GLYCOENGINEERING OF PHARMACEUTICAL CELL LINES 30 FC ENGINEERING: DESIGN, EXPRESSION, AND FUNCTIONAL CHARACTERIZATION OF ANTIBODY VARIANTS WITH IMPROVED EFFECTOR FUNCTION 31 FC ENGINEERING: SERUM HALF-LIFE MODULATION THROUGH FCRN BINDING 32 MONOCLONAL ANTIBODY LEAD CHARACTERIZATION: IN VITRO AND IN VIVO METHODS PART VII INNOVATIVE FORMATS 33 PRODUCTION, PURI?CATION, AND CHARACTERIZATION OF SCFV TNF LIGAND FUSION PROTEINS 34 ANTIBODY-IL2 FUSION PROTEINS FOR TUMOR TARGETING 35 RECOMBINANT IMMUNOTOXINS WITH LOW ENDOTOXINS FOR CLINICAL AND ANIMAL STUDIES 36 CHIMERIC ANTIGEN RECEPTORS FOR T-CELL BASED THERAPY 37 SELECTION AND USE OF INTRACELLULAR ANTIBODIES (INTRABODIES) 38 RADIOLABELED ANTIBODIES FOR CANCER IMAGING AND THERAPY 39 DESIGN AND PRODUCTION OF MULTIMERIC ANTIBODY FRAGMENTS, FOCUSED ON DIABODIES WITH ENHANCED CLINICAL EF?CACY 40 PRODUCTION OF BISPECI?C ANTIBODIES: DIABODIES AND TANDEM SCFV